Loading...
XASE
SCPX
Market cap1mUSD
Jun 05, Last price  
0.04USD
1D
1.43%
1Q
-74.34%
IPO
-99.17%
Name

NightHawk Biosciences Inc

Chart & Performance

D1W1MN
XASE:SCPX chart
No data to show
P/E
P/S
0.16
EPS
Div Yield, %
Shrs. gr., 5y
115.63%
Rev. gr., 5y
31.52%
Revenues
7m
+16.95%
187,7873,110000341,6431,519,9435,793,8493,049,1042,947,9692,112,8065,980,9936,994,838
Net income
-45m
L+3.09%
-2,104,884-2,420,200-8,711,348-11,788,817-20,295,000-12,573,952-11,841,671-15,733,854-20,384,716-27,694,186-35,400,807-43,862,197-45,217,168
CFO
-32m
L+453.17%
-1,649,099-2,073,675-6,388,868-9,829,427-17,447,000-13,523,717-6,303,672-21,711,691-12,837,650-22,021,359-38,128,906-5,700,364-31,532,595
Earnings
Aug 18, 2025

Profile

NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
IPO date
Jul 24, 2013
Employees
77
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
6,995
16.95%
5,981
183.08%
Cost of revenue
49,027
50,993
Unusual Expense (Income)
NOPBT
(42,032)
(45,012)
NOPBT Margin
Operating Taxes
(571)
(3,289)
Tax Rate
NOPAT
(41,461)
(41,723)
Net income
(45,217)
3.09%
(43,862)
23.90%
Dividends
Dividend yield
Proceeds from repurchase of equity
66
60
BB yield
Debt
Debt current
2,613
791
Long-term debt
26,655
17,991
Deferred revenue
30
32
Other long-term liabilities
(31,037)
Net debt
26,877
10,839
Cash flow
Cash from operating activities
(31,533)
(5,700)
CAPEX
(1,986)
(20,118)
Cash from investing activities
32,237
10,992
Cash from financing activities
(8,952)
(4,907)
FCF
(39,609)
(79,126)
Balance
Cash
2,391
44,272
Long term investments
(36,328)
Excess cash
2,042
7,645
Stockholders' equity
(257,419)
(210,583)
Invested Capital
299,785
260,274
ROIC
ROCE
EV
Common stock shares outstanding
130
25,606
Price
Market cap
EV
EBITDA
(35,558)
(41,867)
EV/EBITDA
Interest
777
2,821
Interest/NOPBT